Metagenomi SEC Filings

MGX NASDAQ

Welcome to our dedicated page for Metagenomi SEC filings (Ticker: MGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Parsing a biotech filing that combines gene-editing jargon with clinical-trial risk disclosures isn’t easy. Metagenomi’s 10-K can exceed 200 pages detailing its metagenomics-derived nucleases, partnership milestones and cash burn. That complexity sends most investors hunting for a clear roadmap to revenue and safety data. If you’ve ever searched “Metagenomi SEC filings explained simply” or asked where to see “Metagenomi insider trading Form 4 transactions,” this page was built for you.

Stock Titan’s AI-powered analysis turns every new document—from a Metagenomi quarterly earnings report 10-Q filing to an urgent 8-K—into concise, plain-English summaries. Our models highlight cash runway, IND timelines and collaboration payments, while real-time alerts surface Metagenomi Form 4 insider transactions real-time so you can track executive stock moves before the market reacts. Investors searching for Metagenomi executive stock transactions Form 4 will see the data seconds after it hits EDGAR. Need deeper context? Click into the full text; AI callouts show exactly where revenue by program, R&D expense shifts, or risk factor updates live, saving hours of manual scrolling.

Whether you’re comparing pipeline progress quarter over quarter, gauging dilution risk, or monitoring governance through the Metagenomi proxy statement executive compensation tables, you’ll find every filing type in one place. Investors regularly use our platform to review a Metagenomi annual report 10-K simplified, assess Metagenomi earnings report filing analysis, or clarify Metagenomi 8-K material events explained. By understanding Metagenomi SEC documents with AI you act on data, not speculation.

07/09/2025 06:34 PM

Filing

[144] Metagenomi, Inc. SEC Filing

Rhea-AI Summary

Lucerne Capital Management LP and its principals have converted their passive Schedule 13G status into an active Schedule 13D, signalling a potentially more hands-on approach toward ADS-TEC Energy PLC (NASDAQ: ADSE). The group – consisting of Lucerne Capital Management LP, Pieter Taselaar, Matheus Hovers, Jonathan Copplestone and Patrick Moroney – now reports beneficial ownership of 12,662,214 Class A shares, or 20.5 % of ADSE’s 53,876,307 shares outstanding. Lucerne itself holds sole voting/dispositive power over 11,232,220 shares, while the remaining 1,429,994 shares are held with shared power among the reporting persons.

How the stake was accumulated

Initial equity obtained through the August 2021 business-combination with European Sustainable Growth Acquisition Corp.
Open-market purchases (details in Annex A).
Participation in private placements and three secured lending rounds (May 2023, Aug 2023 and Aug 2024) totalling undisclosed principal; loans carry 10 % p.a. interest and mature 31 Aug 2026.
As consideration for the loans, Lucerne received multiple warrant packages: $3.00 strike (exp. 31 Aug 2025) and $6.20 strike (exp. 26 Aug 2026). Warrants exercisable within 60 days are included in the 20.5 % ownership figure.

Intentions going forward

The filing states that the stake is held for investment purposes but that the group will “review such investment on a continuing basis.” Consistent with activist language, the investors may acquire additional shares, dispose of shares, or enter derivatives, and have reserved the right to engage with management, other shareholders and the Board on strategy, financing, governance and other corporate matters.

Implications for shareholders

A single investor controls more than one-fifth of the float, potentially influencing strategic direction, financing terms and Board composition.
The 10 % secured loans supplied near-term liquidity to ADSE but at a relatively high cost and with additional dilution potential through in-the-money warrants (current share price undisclosed in the filing).
The switch from 13G to 13D raises the probability of activist proposals, strategic reviews or capital structure changes before the 2026 warrant/loan maturities.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

FAQ

What is the current stock price of Metagenomi (MGX)?

The current stock price of Metagenomi (MGX) is $2.25 as of July 14, 2025.

What is the market cap of Metagenomi (MGX)?

The market cap of Metagenomi (MGX) is approximately 63.2M.

What is the primary focus of Metagenomi?

Metagenomi is dedicated to precision genetic medicine, focusing on developing curative therapeutics by leveraging a comprehensive, metagenomics-derived gene editing toolbox.

How does Metagenomi utilize its metagenomics platform?

The company taps into billions of years of microbial evolution to discover unique enzymatic activities, which are then optimized to create innovative gene editing tools with high specificity and efficacy.

What types of gene editing tools does Metagenomi develop?

Metagenomi develops a range of tools including programmable nucleases, cutting-edge base editors, and RNA/DNA-mediated integration systems, all designed to target a wide array of genetic mutations.

How does Metagenomi differentiate itself in the competitive gene editing space?

Its use of a metagenomics-driven discovery process combined with advanced AI-assisted design allows Metagenomi to produce highly specific, efficient, and durable gene editing systems that address challenges unresolvable by conventional methods.

Which therapeutic areas are targeted by Metagenomi?

While the company’s lead programs include conditions such as hemophilia A, its technology platform is versatile enough to potentially address a broad spectrum of genetic disorders that involve diverse mutations.

How does artificial intelligence contribute to Metagenomi's technology?

AI is integrated into the discovery and optimization processes to rapidly generate novel gene editing systems, enhancing precision and efficiency while reducing development time for new therapeutic tools.

What is the significance of the hemophilia A program?

The hemophilia A program highlights Metagenomi’s ability to achieve durable therapeutic protein expression through targeted gene integration, marking a pivotal step towards potential one-time curative treatments for patients with bleeding disorders.

How does Metagenomi ensure the precision and safety of its gene editing applications?

Through rigorous preclinical studies, detailed validation processes, and active regulatory engagement, Metagenomi prioritizes specificity and safety in its gene editing techniques, building trust and maintaining high scientific standards.